Yes ESPR did get crushed today. Despite this beating, ESPR’s market cap is still 6.5-7 times that of RVX on a currency adjusted basis. Doesn’t say much for RVX management capabilities.

This is only one study, and I haven’t really been following the LDL space (other than ESPR as an example of a well run business), but I wonder if other LDL studies show this non effect on MACE despite end point success. If this is the case might it mean that LDL reduction therapies have gone as far as they can go in reducing MACE?  This is a question not a statement.  It might bode well for RVX if this is the case and BETOnMACE and RVX are successful.